Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)–Optimizing Use of Current Options
From Quandary to Clarity in Relapsed/Refractory Multiple Myeloma: Optimizing Treatment and Empowering Patients
Activity 1: Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)–Optimizing Use of Current Options
Multiple myeloma (MM), a hematologic malignancy plagued by multiple relapses, has seen notable progress in care that has led to improved survival. Contributing to the progress has been an increased understanding of MM pathogenesis and cytogenetics-based risk stratification and the availability of therapeutics such as immunomodulatory drugs, proteasome inhibitors, and novel targeted therapies. Keeping up with these advances is especially challenging for community-based clinicians for whom MM may represent only a small fraction of their total patient population.
With the continued rapid pace of advances in MM, management of patients with relapsed/ refractory (RR) disease is becoming increasingly complex and requires careful evaluation and interpretation of new and emerging data. To help advanced practitioners (APs) enhance their roles as educators and advocates, strategies for effectively educating patients and engaging them in shared decision making are also needed.
From Quandary to Clarity in Relapsed/Refractory Multiple Myeloma: Optimizing Treatment and Empowering Patients is an educational initiative designed to improve the ability of APs to provide high-quality care for patients with RRMM. This initiative includes:
- 3 expert clinical dialogues (video-based activities) certified for continuing education credit
- Downloadable resources including transcripts and slides for each of the certified activities and links to related guidelines, articles, and websites
- Downloadable patient education materials
Release date: July 31, 2019
Expiration date: July 31, 2020
Estimated time to complete: 0.5 hour
This activity is designed to help clinicians achieve specific learning objectives, which reflect the desired results of the education. Participants are encouraged to integrate what they learn from this activity into practice to improve patient care and outcomes.
Jointly provided by
Sandra Kurtin, PhD, ANP-C, AOCN®, The University of Arizona Cancer Center, Tucson, Arizona
Kevin Brigle, PhD, ANP, Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Josh Epworth, MSN, ARNP, University of Washington, Seattle, Washington
This activity is designed for community-based advanced practitioners (eg, nurse practitioners, advanced practice nurses, physician assistants, oncology pharmacists) who provide care for patients with RRMM. Those practicing in academic and comprehensive cancer centers may also choose to participate.
After completing this activity, clinicians should be better able to:
- Relate the mechanism of action of current and/or emerging therapies for RRMM to their expected and proven therapeutic effects and toxicities
- Interpret the clinical significance of findings from clinical trials supporting the efficacy and safety of approved and/or emerging therapeutic regimens and strategies for RRMM
- Plan strategies for selecting and sequencing therapy for patients with RRMM
- Identify potential adverse events associated with approved and/or novel agents used to treat RRMM
- Devise strategies for mitigating adverse events associated with therapies for RRMM
This activity is certified for credit by Annenberg Center for Health Sciences at Eisenhower.
39000 Bob Hope Drive, Dinah Shore Building, Rancho Mirage, CA 92270
Voice: 760-773-4500; Fax: 760-773-4513; E-mail: email@example.com
© 2019, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.
Statement of Credit
Participants who successfully complete this activity—which includes submitting a completed pre-test, submitting and scoring at least 70% on the post-test, and submitting a completed evaluation form—will be able to download a statement of credit.
To access the learning assessment and evaluation form, visit https://education.annenberg.net/5741-1
Accreditation and Designation Statements
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.5 contact hour may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider No. 13664, for 0.5 contact hour.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been assigned ACPE Universal Program #0797-9999-19-064-H01-P. This activity is designated for up to 0.5 contact hour (0.05 CEU) of continuing pharmacy education credit. This is a knowledge-based activity.
This activity is supported by educational grants from AbbVie Inc. and Celgene Corporation.
Relationships of Faculty and Planners
All individuals in a position to control the content of this activity (eg, planners, faculty, reviewers) must disclose all financial relationships with commercial interests that may have a bearing on its subject matter. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with its policies and procedures. Participants should assess the impact (if any) of the disclosed information on the educational value of the activity.
Sandra Kurtin, PhD, ANP-C, AOCN®, is a consultant for AbbVie, Acceleron, Amgen, Celgene, Genentech, Incyte, Novartis, and Pharmacyclics.
Kevin Brigle, PhD, ANP, is on the speakers bureau for Amgen, AstraZeneca, Celgene, Genentech, Novartis, and Takeda.
Josh Epworth, MSN, ARNP, has nothing to disclose.
Planners and Reviewers
Staff of and consultants for the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education have nothing to disclose.
This activity may include discussion of agents that have not yet been approved by the U.S. Food and Drug Administration and investigational uses of approved products. Please consult prescribing information and practice guidelines for detail regarding safe and effective use of therapeutic agents.
The opinions expressed in this activity are those of the faculty and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any therapeutic agent or approach to diagnosis or patient management.
- 0.50 ACPE
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Attendance
- 0.50 CA-BRN
- 0.50 ANCC